Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
Scorpius Holdings (NYSE American: SCPX) has received a delisting notice from NYSE American due to the low selling price of its common stock. The company also received a non-compliance notice for failing to file its Form 10-K for the period ended December 31, 2024, by the April 15, 2025 deadline.
The CDMO company cited time constraints on management and potential undue hardship and expense as reasons for the delayed filing in their Form 12b-25 notification. Scorpius plans to appeal the delisting decision and will request a review by the Exchange's Listings Qualifications Panel.
CEO Jeff Wolf stated the company is actively working to achieve full compliance with SEC requirements and will provide updates as they become available. While the appeal's outcome remains uncertain, Scorpius maintains its commitment to transparency, regulatory compliance, and maximizing shareholder value.
Scorpius Holdings (NYSE American: SCPX) ha ricevuto una comunicazione di esclusione dalla quotazione da parte di NYSE American a causa del basso prezzo di vendita delle sue azioni ordinarie. L'azienda ha inoltre ricevuto un avviso di non conformità per non aver presentato il modulo 10-K relativo al periodo terminato il 31 dicembre 2024 entro la scadenza del 15 aprile 2025.
La società CDMO ha indicato, nella notifica del modulo 12b-25, limitazioni di tempo per la direzione e possibili difficoltà e costi eccessivi come motivazioni per il ritardo nella presentazione. Scorpius intende presentare ricorso contro la decisione di esclusione e richiederà una revisione da parte del Panel di Qualifica delle Quotazioni della Borsa.
Il CEO Jeff Wolf ha dichiarato che l’azienda sta lavorando attivamente per raggiungere la piena conformità con i requisiti della SEC e fornirà aggiornamenti non appena disponibili. Sebbene l'esito del ricorso sia incerto, Scorpius conferma il suo impegno per la trasparenza, il rispetto delle normative e la massimizzazione del valore per gli azionisti.
Scorpius Holdings (NYSE American: SCPX) ha recibido un aviso de exclusión de cotización por parte de NYSE American debido al bajo precio de venta de sus acciones ordinarias. La compañía también recibió un aviso de incumplimiento por no presentar el Formulario 10-K correspondiente al período finalizado el 31 de diciembre de 2024 antes de la fecha límite del 15 de abril de 2025.
La empresa CDMO señaló, en su notificación del Formulario 12b-25, limitaciones de tiempo en la dirección y posibles dificultades y gastos excesivos como razones para la demora en la presentación. Scorpius planea apelar la decisión de exclusión y solicitará una revisión por parte del Panel de Calificación de Listados de la Bolsa.
El CEO Jeff Wolf declaró que la compañía está trabajando activamente para cumplir plenamente con los requisitos de la SEC y proporcionará actualizaciones tan pronto como estén disponibles. Aunque el resultado de la apelación es incierto, Scorpius mantiene su compromiso con la transparencia, el cumplimiento normativo y la maximización del valor para los accionistas.
Scorpius Holdings (NYSE American: SCPX)는 보통주의 낮은 매도가격으로 인해 NYSE American으로부터 상장폐지 통보를 받았습니다. 회사는 또한 2024년 12월 31일 종료된 기간에 대한 Form 10-K를 2025년 4월 15일 마감일까지 제출하지 않아 비준수 통보를 받았습니다.
CDMO 회사는 Form 12b-25 통지서에서 경영진의 시간 부족과 과도한 부담 및 비용 가능성을 지연 제출 사유로 언급했습니다. Scorpius는 상장폐지 결정에 대해 항소할 계획이며, 거래소 상장 자격 심사 위원회의 검토를 요청할 예정입니다.
CEO 제프 울프는 회사가 SEC 요구사항을 완전히 준수하기 위해 적극적으로 노력하고 있으며, 가능한 한 빨리 업데이트를 제공할 것이라고 밝혔습니다. 항소 결과는 불확실하지만, Scorpius는 투명성, 규제 준수 및 주주 가치 극대화에 대한 약속을 유지하고 있습니다.
Scorpius Holdings (NYSE American : SCPX) a reçu un avis de radiation de la part de NYSE American en raison du faible prix de vente de ses actions ordinaires. La société a également reçu un avis de non-conformité pour ne pas avoir déposé son formulaire 10-K pour la période clôturée au 31 décembre 2024 avant la date limite du 15 avril 2025.
La société CDMO a indiqué dans sa notification Formulaire 12b-25 des contraintes de temps pour la direction ainsi que des difficultés et dépenses potentielles excessives comme raisons du retard de dépôt. Scorpius prévoit de faire appel de la décision de radiation et sollicitera un examen par le Panel des Qualifications de Cotation de la Bourse.
Le PDG Jeff Wolf a déclaré que la société travaille activement à la pleine conformité avec les exigences de la SEC et fournira des mises à jour dès qu'elles seront disponibles. Bien que l'issue de l'appel reste incertaine, Scorpius réaffirme son engagement envers la transparence, le respect réglementaire et la maximisation de la valeur pour les actionnaires.
Scorpius Holdings (NYSE American: SCPX) hat von der NYSE American eine Delisting-Benachrichtigung aufgrund des niedrigen Verkaufspreises seiner Stammaktien erhalten. Das Unternehmen erhielt außerdem eine Nicht-Einhaltungsbenachrichtigung, da es seine Form 10-K für den zum 31. Dezember 2024 endenden Zeitraum nicht bis zur Frist am 15. April 2025 eingereicht hat.
Das CDMO-Unternehmen gab in seiner Form 12b-25-Mitteilung Zeitmangel im Management sowie mögliche unzumutbare Härten und Kosten als Gründe für die verspätete Einreichung an. Scorpius plant, gegen die Delisting-Entscheidung Berufung einzulegen und wird eine Überprüfung durch das Listing Qualifications Panel der Börse beantragen.
CEO Jeff Wolf erklärte, dass das Unternehmen aktiv daran arbeitet, die vollständige Einhaltung der SEC-Anforderungen zu erreichen, und Updates bereitstellen wird, sobald diese verfügbar sind. Obwohl das Ergebnis der Berufung ungewiss ist, bleibt Scorpius seinem Engagement für Transparenz, regulatorische Compliance und die Maximierung des Aktionärswerts treu.
- None.
- Received NYSE American delisting notice due to low stock price
- Failed to file Form 10-K by deadline, triggering non-compliance notice
- Management unable to complete financial reporting requirements timely
- Risk of potential delisting from NYSE American exchange
Insights
Scorpius faces NYSE American delisting over low stock price and late 10-K filing; appeal outcome uncertain despite management's commitments.
Scorpius Holdings (
The company's explanation for the delayed filing—citing "time constraints" and that timely filing would cause "undue hardship and expense"—lacks specificity and raises governance concerns. Notably absent from the announcement is any concrete timeline for when the company expects to file the overdue annual report or specific remediation plans to address the low stock price issue.
Scorpius has indicated it will appeal the delisting determination through the Exchange's Listings Qualifications Panel, but explicitly acknowledges there is "no assurance regarding the outcome." During delisting proceedings, trading typically continues, though often with additional designations alerting investors to compliance issues.
For context, the NYSE American typically requires companies to maintain a share price above
The combination of extremely low share price and failure to file timely financial statements creates a compounded compliance problem that typically requires substantial remediation efforts. While CEO Jeff Wolf expressed commitment to transparency and compliance, the announcement lacks specific details on how and when the company intends to resolve these fundamental issues.
San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice from the NYSE American LLC (“NYSE American” or the “Exchange”) of its determination to commence delisting proceedings of the Company’s common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low-selling price of the Company’s common stock.
In addition, on April 16, the Company received an official notice of noncompliance from NYSE Regulation stating that the Company is not in compliance with NYSE American continued listing standards under the timely filing criteria included in Section 1007 of the NYSE American Company Guide due to the failure to timely file the Company’s Form 10-K for the period ended December 31, 2024 by the filing due date of April 15, 2025. As previously reported in the Company’s Notification of Late Filing on Form 12b-25 filed with the SEC on March 31, 2025, the Company was unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 within the prescribed period because the compilation, dissemination and review of the financial information required to be presented in the Annual Report on Form 10-K imposed time constraints on the Company’s management that rendered timely filing of the Annual Report on Form 10-K impractical without undue hardship and expense to the Company.
The Company plans to appeal the NYSE American’s decision to commence delisting proceedings of the Company’s common stock. Specifically, the Company intends to request a review of the determination by the Exchange’s Listings Qualifications Panel. While there can be no assurance regarding the outcome of the appeal, Scorpius remains committed to continued operational and strategic progress.
Scorpius CEO Jeff Wolf commented, “We are actively working to become a fully compliant company with the U.S. Securities and Exchange Commission, and will provide further updates as they become available. We remain undeterred in our commitment to transparency, regulatory compliance, and maximizing long-term value for shareholders.”
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the Company’s ability to file its Annual Report on Form 10-K during the Initial Cure Period; the plans to appeal the NYSE American’s decision to commence delisting proceedings of the Company’s common stock; the intent to request a review of the determination by the Exchange’s Listings Qualifications Panel; and the Company’s ability to regain compliance with the NYSE American continued listing standards and successfully appeal the NYSE American’s decision to commence delisting proceedings of the Company’s common stock. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to regain compliance with the NYSE American continued listing standards continue to grow revenue; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
Why is Scorpius Holdings (SCPX) facing delisting from NYSE American?
What steps is SCPX taking to address the NYSE American delisting notice?
When did SCPX miss its Form 10-K filing deadline?
What reason did SCPX provide for missing the 10-K filing deadline?
